AstraZeneca is leaving no stone unturned in its effort to make baxdrostat the first aldosterone synthase inhibitor (ASI) to get approval for hard-to-treat hypertension. The FDA has now started a review of the highly anticipated drug, and AZ is using a priority review voucher to shorten the timeline for a potential approval to the second…
Astrazeneca Baxdrostat application accepted for priority review by USFDA for hard-to-control hypertension We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Baxdrostat Shows Significant Blood Pressure Reduction in Resistant Hypertension in Phase III trial We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
AstraZeneca’s baxdrostat has hit the mark in another phase 3 trial involving people who struggle to control their blood pressure with current therapies, keeping the would-be blockbuster on track for regulatory filings this year. The latest top-line readout from the Bax24 study in patients with resistant hypertension showed that baxdrostat achieved a statistically significant reduction…
Promising new drug for people with stubborn high blood pressure: NEJM We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link